Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy

The previous AVAPERL trial demonstrated that induction therapy with first-line cisplatin (CDDP), pemetrexed (PEM) and bevacizumab (BEV), followed by continuation maintenance therapy with PEM+BEV, improved the progression-free survival (PFS) and overall survival (OS) compared with BEV alone (median P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Nakashima, Kazuhisa, Murakami, Haruyasu, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Endo, Masahiro, Takahashi, Toshiaki
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5103868/
https://ncbi.nlm.nih.gov/pubmed/27900087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados